Study Details To assess the safety and tolerability of single escalating doses of CAN106
Protocol Number CAN106
Phase I
Therapeutic Area Haematology
Subject Types Healthy
Indication PNH
Principal Investigator Dr Khoo Chin Meng
Investigator Product / Device CAN106
Sponsor CARE Pharma Shanghai Ltd
Top